Peripheral blood stem cell mobilization for high-dose chemotherapy

Area of Science:

• Hematology
• Transplantation Medicine
• Oncology

Background:

• Peripheral blood stem cells (PBSC) are increasingly used in transplantation.
• PBSC transplantation demonstrates faster hematopoietic recovery compared to traditional bone marrow.
• This leads to significant reductions in hospitalization duration, transfusion needs, and overall costs.

Purpose of the Study:

• To evaluate the efficacy of growth factor-mobilized PBSC in hematopoietic recovery.
• To identify key predictors of successful stem cell engraftment.
• To compare PBSC transplantation with bone marrow transplantation.

Main Methods:

• Analysis of studies comparing hematopoietic recovery times between PBSC and bone marrow.
• Assessment of the impact of CD34+ cell dose on engraftment.
• Identification of patient-specific factors influencing stem cell yield.

Main Results:

• PBSC transplantation shows significantly faster engraftment of neutrophils and platelets (8-12 days) versus bone marrow (2-4 weeks).
• Higher CD34+ cell counts (> or =5 x 10(6) cells/kg) strongly predict rapid hematopoietic recovery.
• Factors like age, prior radiation, marrow involvement, and chemotherapy influence stem cell yield.

Conclusions:

• PBSC transplantation offers superior and faster hematopoietic recovery, making it the preferred method over bone marrow for autologous transplantation.
• CD34+ cell dose is the most critical factor for predicting engraftment success.
• Identifying patients likely to have poor stem cell mobilization is crucial for optimizing transplantation strategies.